Risk of Nephrogenic Systemic Fibrosis in Liver Transplantation Patients
American Journal of Roentgenology, 09/02/2011
Chow DS et al. – Within the institution, only 0.1% (1/709) of all liver transplantation patients exposed to gadolinium–based contrast agents or 1.4% (1/74) of CKD5 patients requiring dialysis had biopsy proof of nephrogenic systemic fibrosis (NSF). This incidence is consistent with the rate of NSF in all patients exposed to gadolinium–based contrast agents regardless of liver transplantation reported in the literature. Therefore, liver transplantation may not be an independent risk factor in development of NSF in patients exposed to gadolinium–based contrast agents.





